[News] ESMO Congress 2023

EV-302, an international, randomised, phase 3 trial investigated the efficacy of enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with untreated, locally advanced, metastatic urothelial carcinoma. Thomas B Powles (Barts Cancer Institute, London, UK) reported the final analysis of dual primary endpoints of progression-free survival by BICR and overall survival. After a median follow-up of 17·2 months, among the 442 patients randomly assigned to the experimental group and 444 to the chemotherapy group, progression free survival was significantly improved (12·5 months vs 6·3 months; HR 0·45 [95% CI 0·38–0·54]; p<0.0001) and median overall survival was almost doubled in the experimental group (31·5 months vs 16·1 months; HR 0·47 [0·38–0·58]; p<0·0001]).